EMCURE PHARMACEUTICALS LIMITED

Issue Date Price Band Bid Lot Registar BRLM
03 Jul, 2024 - 05 Jul, 2024 ₹ 960 - 1008 14 shares & in multiples LINKINTIME AXIS, KOTAK, JP

Subscription Level As On : 05-Jul-2024 11:59:07 PM

Category Book Size Subscription
No. of Shares Offered Amount No. of Shares Bid Amount No. of Times
@ Upper @ Upper
QIB 37,62,896 3,79,29,99,168 73,68,91,932 7,42,78,70,67,456 195.83
NII 29,49,523 2,97,31,19,184 14,25,26,748 1,43,66,69,61,984 48.32
NII (Above 10 lacs) 19,66,349 1,98,20,79,792 10,57,70,490 1,06,61,66,53,920 53.79
NII (2-10 lacs) 9,83,174 99,10,39,392 3,67,56,258 37,05,03,08,064 37.39
Retail 68,82,219 6,93,72,76,752 4,96,18,982 50,01,59,33,856 7.21
Employee 1,08,900 10,97,71,200 9,59,728 96,74,05,824 8.81
Total 1,37,03,538 13,81,31,66,304 92,99,97,390 9,37,43,73,69,120 67.87
www.ognajwala.in Applications : 28,71,090 (5.96)

Chirag Shah (Ognajwala)

Disclaimer: The above-mentioned information/data are sourced from the websites of the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) and are subject to change on a real-time basis. For updated information/data, you can visit their respective website. The information/data provided herein above are for information purposes only and provided by Ognajwala.in on an "AS IS" and "AS AVAILABLE" basis and without warranty, express or implied. Ognajwala.in does not guarantee or warrant the accuracy, adequacy, or completeness of the information received through the said websites. Ognajwala.in holds no responsibility of any kind as regards any discrepancies, errors, omissions, losses, or damages. Ognajwala.in including its affiliates and any of its officers, directors, personnel, and employees, shall not be liable for any loss, or damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of information/data received through the said websites. The recipient alone shall be fully responsible/liable for any decision taken based on such information/data. All recipients should before acting upon the said information make their investigation, and seek appropriate professional advice.